Ken Griffin Kura Oncology, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,800 shares of KURA stock, worth $201,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,800
Previous 8,200
19.51%
Holding current value
$201,782
Previous $117,000
78.63%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding KURA
# of Institutions
173Shares Held
80.4MCall Options Held
914KPut Options Held
120K-
Suvretta Capital Management, LLC New York, NY7.07MShares$146 Million6.46% of portfolio
-
Black Rock Inc. New York, NY6.9MShares$142 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$120 Million3.53% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$111 Million2.38% of portfolio
-
Bvf Inc San Francisco, CA4.79MShares$98.5 Million3.06% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.38B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...